Many kinase inhibitors for cancer therapy are rather nonselective, and their cellular mechanisms of action are incompletely understood. A nested chemical proteomics and chemical genetics strategy reveals which cellular targets of the clinical kinase inhibitor dasatinib functionally relate to its anti-oncogenic activity.
References
Karaman, M.W. et al. Nat. Biotechnol. 26, 127–132 (2008).
Rix, U. & Superti-Furga, G. Nat. Chem. Biol. 5, 616–624 (2009).
Li, J. et al. Nat. Chem. Biol. 6, 291–299 (2010).
Huang, F. et al. Cancer Res. 67, 2226–2238 (2007).
Sos, M.L. et al. J. Clin. Invest. 119, 1727–1740 (2009).
Blencke, S. et al. Chem. Biol. 11, 691–701 (2004).
Hantschel, O. et al. Proc. Natl. Acad. Sci. USA 104, 13283–13288 (2007).
Haura, E.B. et al. J. Clin. Oncol. published online, doi:10.1200/JCO.2009.25.4029 (8 February 2010).
Downward, J. Nature 462, 44–45 (2009).
Pan, C., Olsen, J.V., Daub, H. & Mann, M. Mol. Cell. Proteomics 8, 2796–2808 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.D. is a shareholder of and has a consultancy agreement with Kinaxo Biotechnologies GmbH.
Rights and permissions
About this article
Cite this article
Daub, H. Narrowing down the real targets. Nat Chem Biol 6, 249–250 (2010). https://doi.org/10.1038/nchembio.336
Issue Date:
DOI: https://doi.org/10.1038/nchembio.336
- Springer Nature America, Inc.